Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies

<b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/...

Full description

Saved in:
Bibliographic Details
Main Authors: Inmaculada Ruiz-Lorente, Lourdes Gimeno, Alicia López-Abad, Pedro López Cubillana, Tomás Fernández Aparicio, Lucas Jesús Asensio Egea, Juan Moreno Avilés, Gloria Doñate Iñiguez, Pablo Luis Guzmán Martínez-Valls, Gerardo Server, Belén Ferri, José Antonio Campillo, María Victoria Martínez-Sánchez, Alfredo Minguela
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/1/156
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832588964325752832
author Inmaculada Ruiz-Lorente
Lourdes Gimeno
Alicia López-Abad
Pedro López Cubillana
Tomás Fernández Aparicio
Lucas Jesús Asensio Egea
Juan Moreno Avilés
Gloria Doñate Iñiguez
Pablo Luis Guzmán Martínez-Valls
Gerardo Server
Belén Ferri
José Antonio Campillo
María Victoria Martínez-Sánchez
Alfredo Minguela
author_facet Inmaculada Ruiz-Lorente
Lourdes Gimeno
Alicia López-Abad
Pedro López Cubillana
Tomás Fernández Aparicio
Lucas Jesús Asensio Egea
Juan Moreno Avilés
Gloria Doñate Iñiguez
Pablo Luis Guzmán Martínez-Valls
Gerardo Server
Belén Ferri
José Antonio Campillo
María Victoria Martínez-Sánchez
Alfredo Minguela
author_sort Inmaculada Ruiz-Lorente
collection DOAJ
description <b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. <b>Methods</b>: We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls. The proliferation and production of cytokines and cytotoxicity were evaluated in peripheral blood mononuclear cells, stimulated in vitro with anti-CD3/CD28 or BCG, from selected patients based on HLA-B −21M/T dimorphism (NKG2A ligands). <b>Results</b>: The HLA-B −21M/T genotype showed opposing results in BC patients treated with BCG or other therapies. The MM genotype, compared to MT and TT, was associated with a longer 75th-percentile overall survival (not reached vs. 68.0 ± 13.7 and 52.0 ± 8.3 months, <i>p</i> = 0.034) in BCG, but a shorter (8.0 ± 2.4 vs. 21.0 ± 3.4 and 19.0 ± 4.9 months, <i>p</i> = 0.131) survival in other treatments. The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. The MM genotype was associated with higher counts of circulating CD56<sup>bright</sup>, fewer KIR2DL1/L2<sup>+</sup> NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. <b>Conclusions</b>: The HLA-B −21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients.
format Article
id doaj-art-3bf8ac17041b4f94899ad09d9cd2938a
institution Kabale University
issn 2227-9059
language English
publishDate 2025-01-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-3bf8ac17041b4f94899ad09d9cd2938a2025-01-24T13:24:12ZengMDPI AGBiomedicines2227-90592025-01-0113115610.3390/biomedicines13010156Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other TherapiesInmaculada Ruiz-Lorente0Lourdes Gimeno1Alicia López-Abad2Pedro López Cubillana3Tomás Fernández Aparicio4Lucas Jesús Asensio Egea5Juan Moreno Avilés6Gloria Doñate Iñiguez7Pablo Luis Guzmán Martínez-Valls8Gerardo Server9Belén Ferri10José Antonio Campillo11María Victoria Martínez-Sánchez12Alfredo Minguela13Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainUrology Service, Morales Meseguer Hospital, 30008 Murcia, SpainUrology Service, De la Vega Lorenzo Guirao Hospital, 30530 Murcia, SpainUrology Service, Santa Lucia Hospital, 30202 Murcia, SpainUrology Service, Los Arcos Hospital, 30739 Murcia, SpainUrology Service, Reina Sofía Hospital, 30003 Murcia, SpainUrology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainPathology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, SpainImmunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA), Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain<b>Background</b>: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette–Guerin (BCG), and in muscle-invasive BC (MIBC) with anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize the use of these therapies. <b>Methods</b>: We evaluated killer-cell immunoglobulin-like receptors (KIRs) and HLA-I genotyping and the expression of NK cell receptors in circulating T and NK lymphocytes at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 treated with other therapies), as well as in 648 patients with other cancers and 973 healthy donors as controls. The proliferation and production of cytokines and cytotoxicity were evaluated in peripheral blood mononuclear cells, stimulated in vitro with anti-CD3/CD28 or BCG, from selected patients based on HLA-B −21M/T dimorphism (NKG2A ligands). <b>Results</b>: The HLA-B −21M/T genotype showed opposing results in BC patients treated with BCG or other therapies. The MM genotype, compared to MT and TT, was associated with a longer 75th-percentile overall survival (not reached vs. 68.0 ± 13.7 and 52.0 ± 8.3 months, <i>p</i> = 0.034) in BCG, but a shorter (8.0 ± 2.4 vs. 21.0 ± 3.4 and 19.0 ± 4.9 months, <i>p</i> = 0.131) survival in other treatments. The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. The MM genotype was associated with higher counts of circulating CD56<sup>bright</sup>, fewer KIR2DL1/L2<sup>+</sup> NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. <b>Conclusions</b>: The HLA-B −21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients.https://www.mdpi.com/2227-9059/13/1/156bladder cancerimmunotherapyBCGNK cellsNKG2AHLA-E
spellingShingle Inmaculada Ruiz-Lorente
Lourdes Gimeno
Alicia López-Abad
Pedro López Cubillana
Tomás Fernández Aparicio
Lucas Jesús Asensio Egea
Juan Moreno Avilés
Gloria Doñate Iñiguez
Pablo Luis Guzmán Martínez-Valls
Gerardo Server
Belén Ferri
José Antonio Campillo
María Victoria Martínez-Sánchez
Alfredo Minguela
Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
Biomedicines
bladder cancer
immunotherapy
BCG
NK cells
NKG2A
HLA-E
title Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
title_full Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
title_fullStr Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
title_full_unstemmed Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
title_short Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
title_sort differential role of nkg2a hla e interaction in the outcomes of bladder cancer patients treated with i m bovis i bcg or other therapies
topic bladder cancer
immunotherapy
BCG
NK cells
NKG2A
HLA-E
url https://www.mdpi.com/2227-9059/13/1/156
work_keys_str_mv AT inmaculadaruizlorente differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT lourdesgimeno differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT alicialopezabad differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT pedrolopezcubillana differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT tomasfernandezaparicio differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT lucasjesusasensioegea differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT juanmorenoaviles differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT gloriadonateiniguez differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT pabloluisguzmanmartinezvalls differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT gerardoserver differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT belenferri differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT joseantoniocampillo differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT mariavictoriamartinezsanchez differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies
AT alfredominguela differentialroleofnkg2ahlaeinteractionintheoutcomesofbladdercancerpatientstreatedwithimbovisibcgorothertherapies